|Bid||2.0400 x 1000|
|Ask||2.1300 x 800|
|Day's range||1.9900 - 2.1407|
|52-week range||1.3600 - 9.7600|
|Beta (5Y monthly)||1.43|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Acasti Pharma (NASDAQ: ACST) fell by more than 18% in Tuesday trading. The company said that it had closed its merger with Grace Therapeutics; former Acasti shareholders now own 59% of the combined company. The second -- and more concerning -- part of the announcement was that the company would perform an 8-1 reverse split at the start of trading on Aug. 31.
We feel now is a pretty good time to analyse Acasti Pharma Inc.'s ( CVE:ACST ) business as it appears the company may...
Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).